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Abstract
CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in
resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and
cardiovascular disease, result in part from effects of HIV-1 infection on monocyte and macrophage biology. CD163 co-
expression on CD14+CD16++ monocytes has been proposed as a useful biomarker for HIV-1 disease progression and the
presence of HIV associated dementia. Here we investigated CD163 expression on monocyte subsets ex vivo, on cultured
macrophages, and soluble in plasma, in the setting of HIV-1 infection. Whole blood immunophenotyping revealed CD163
expression on CD14++CD16- monocytes but not on CD14+CD16++ monocytes (P=0.004), supported by CD163 mRNA
levels. Incubation with M-CSF induced CD163 protein expression on CD14+CD16++ monocytes to the same extent as
CD14++CD162 monocytes. CD163 expression on CD14++CD16+ monocytes from HIV-infected subjects was significantly
higher than from uninfected individuals, with a trend towards increased expression on CD14++CD162 monocytes (P=0.019
and 0.069 respectively), which is accounted for by HIV-1 therapy including protease inhibitors. Shedding of CD163 was
shown to predominantly occur from the CD14++CD162 subset after Ficoll isolation and LPS stimulation. Soluble CD163
concentration in plasma from HIV-1 infected donors was similar to HIV-1 uninfected donors. Monocyte CD163 expression in
HIV-1 infected patients showed a complicated relationship with classical measures of disease progression. Our findings
clarify technical issues regarding CD163 expression on monocyte subsets and further elucidates its role in HIV-associated
inflammation by demonstrating that CD163 is readily lost from CD14++CD162 monocytes and induced in pro-inflammatory
CD14+CD16++ monocytes by M-CSF. Our data show that all monocyte subsets are potentially capable of differentiating into
CD163-expressing anti-inflammatory macrophages given appropriate stimuli. Levels of CD163 expression on monocytes
may be a potential biomarker reflecting efforts by the immune system to resolve immune activation and inflammation in
HIV-infected individuals.
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Introduction
With the success of antiretroviral therapy in reducing the
incidence of AIDS, attention is now turning to non-AIDS co-
morbidities in chronically HIV-infected individuals. Two such
important age-related co-morbidities that are accelerated in HIV-
1 infection are cardiovascular disease and HIV-1 associated
dementia, both of which involve activated macrophages and
chronic inflammation [1,2,3,4]. Biomarkers that detect persistent
inflammation are needed to monitor immune activation and
inflammation to enable better long term clinical outcomes for
HIV-infected individuals. The scavenger receptor CD163 has
been investigated as a potential marker of inflammation in
infectious diseases such as meningitis [5], as well as in autoimmune
diseases driven by activated macrophages [6,7,8], and so may have
potential as a monitoring tool in management of HIV-1 disease.
CD163 is a member of the class B scavenger receptor cysteine-
rich superfamily, primarily responsible for endocytosing hemoglo-
bin-haptoglobin (Hb-Hp) complexes [9,10] and, to a lesser degree,
free hemoglobin (Hb) released from hemolysed erythrocytes [11].
Other more recently recognised functions of CD163 include anti-
inflammatory scavenger receptor for the tumour necrosis factor-
like weak inducer of apoptosis (TWEAK) [12], an erythroblast
receptor, promoting their survival and differentiation [13], and a
receptor functioning as an innate immune sensor for both Gram
positive and negative bacteria [14]. CD163 expressing macro-
phages are also involved in resolution of inflammation by limiting
free hemoglobin associated damage [11] and secreting anti-
inflammatory cytokines in response to inflammation [15,16].
However, the immune effects of CD163 are complicated and may
not be limited to down-regulating inflammation as CD163
stimulation has also been reported to induce pro-inflammatory
cytokine production from rat macrophages [17]. In vitro, soluble
CD163, but not membrane bound CD163, inhibits phorbol ester-
induced T cell proliferation [18,19]. CD163 protein expression on
monocytes and macrophages is altered in a number of diseases
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[20,21,22]. CD163 expression is increased by exposure of
monocytes to glucocorticoids in vivo, and incubation with M-
CSF, IL-6 and IL-10 in vitro, [23,24,25,26,27,28] while it is
decreased following incubation with pro-inflammatory cytokines
GM-CSF, IL-4, IFNc and TNFa [25,27,29].
CD163 is shed from the cell surface of monocytes following
proteolytic cleavage after pro-inflammatory stimulation such as
ligand binding (including lipopolysaccharide) to toll-like
receptors [26,30,31,32,33,34]. Soluble CD163 is thought to
be involved in the resolution of inflammation by mechanisms
that are not yet fully understood, but include inhibition of T
cell activation [16,18], and is increased in autoimmune
disorders [32,35,36], hematological malignancies [37], malaria
[38], and bacterial, but not viral meningitis [8]. Macrophage
activation syndrome is driven by activated macrophages (and
poorly functioning natural killer cells) and is associated with
significantly increased plasma levels of soluble CD163 [6,7].
Soluble CD163 levels in plasma correlate inversely with
expression of CD163 on monocytes in blood obtained from
randomly selected hospital patients [39] suggesting that
monocytes are a major source of sCD163 under pathophysi-
ological conditions.
In terms of HIV-1, productively infected macrophages and
microglia in the brain of individuals with HIV-related enceph-
alitis have been shown to upregulate CD163 [3,40,41]. In
peripheral blood, the number of CD14+CD16++ monocytes
expressing CD163 correlates with SIV RNA in plasma in SIV-
infected rhesus macaques [40]. Levels of soluble CD163 in
plasma of SIV-infected macaques correlate with monocyte
activation and expansion [42]. In SIV-infected macaques with
myocarditis, there was a correlation between CD163-expression
on macrophages and the numbers of SIV-infected cells, but there
were lower numbers of intra-cardiac CD163-expressing macro-
phages in SIV-infected macaques with myocarditis compared to
controls, suggesting these cells are associated with decreased
inflammation in the heart [43].
There have been contradictory reports on the expression of
CD163 on different monocyte subsets with some studies reporting
highest expression on the non-classical CD14+CD16++ mono-
cytes [25,44] while others report highest expression on
CD14++CD162 monocytes [20]. CD163 is much more labile
on monocytes than other surface molecules such as CD36 [45] and
its expression on monocytes is altered both by the anticoagulant
used in blood sampling and during purification of peripheral blood
mononuclear cells [41,45]. Recently it has been shown that
inconsistencies in reported expression of CD163 on blood
monocytes may also result from different sources of antibodies
used for analysis, with epitope accessibility and CD163 detection
being highest with antibodies directed against the N terminal of
CD163 [46].
Given the proposed role of CD163-expressing monocytes in
resolution of inflammation, and the potential for use of soluble
CD163 as a marker for inflammation for HIV-infected individuals,
we aimed to characterise CD163 expression on monocyte subsets
and soluble levels in plasma in the setting of HIV-1 infection. We
show that CD163 is more highly expressed on CD14++CD16-
compared to CD14++CD16+ monocytes, and not expressed on
CD14+CD16++ monocytes, at the level of both protein and gene
expression, and that expression is increased in HIV-1 infection.
Soluble CD163 in plasma was not significantly altered by HIV-1
infection. CD163 expression increased during maturation into




All human blood samples used in this study were collected with
informed consent and approval from The Alfred Hospital Human
Research Ethics Committee, project number 128/06 (Melbourne,
Victoria, Australia).
Sample donors
Peripheral blood was collected in K3EDTA tubes (BD
Bioscience) from HIV-1 infected volunteers attending the Alfred
Hospital Infectious Diseases Unit Outpatients (Melbourne,
Victoria, Australia) or healthy HIV-1 uninfected laboratory
volunteers. Controls were age matched to HIV-1 infected donors
(HIV-1 negative median 40 yr vs. HIV-1 positive median age
42 yr). Table S1 describes the viral load, CD4 T cell count and
antiretroviral therapy regimen of HIV-1 positive donors at time
of recruitment. To harvest plasma, K3EDTA tubes containing
blood samples were centrifuged at 6206g for 10 min with no
brake. The uppermost 3 ml was removed and stored at 280uC
until analysed.
Whole blood flow cytometry phenotyping
All antibodies used were purchased from BD Biosciences. An
antibody cocktail composed of 8 ml anti-CD14 FITC or 4 ml anti-
CD14 APC-Cy-7, 8 ml anti-CD16 PC5 and 8 ml CD163-PE (clone
GHI/61; directed against domain 7 of CD163) or IgG-1 PE was
placed in 5 ml polypropylene FACS tubes (BD Biosciences) and
80 ml of whole blood was added. The mixture was vortexed and
incubated on ice for 30 min. Erythrocytes were lysed with 1 ml
Facs Lyse (BD Biosciences) for 10 min then cells centrifuged at
5006g for 7 min at 4uC, with 3 ml PBS containing 1% newborn
calf serum (Cosmic calf serum, HyClone) and 2 mM EDTA (wash
buffer). Monocytes were initially gated using forward vs. side
scatter dot plots. These events were then gated onto a CD14 vs.
CD16 dot plot and monocyte subsets defined as described in
figure 1A using recently defined nomenclature [47]. CD163
expression was defined as the proportion of cells within a given
monocyte gate with fluorescence greater than that expressed by
approximately 2% of isotype matched control cells (IgG-1 PE, BD
Biosciences).
LPS stimulation
100 ml of whole blood was washed (5006g, 7 min, 4uC) with
4 ml sterile wash buffer then resuspended in 1 ml supplemented
Iscoves modified Dulbecco’s medium (IMDM) containing 10%
human serum (described below) with or without 1 mg/ml
lipopolysaccharide (LPS). Cells were incubated for 2 hours at
37uC prior to washing and staining as described above.
CD163 ELISA
Soluble CD163 from EDTA plasma samples was quantified in
2 ml of plasma using a commercial ELISA kit (BMA Biomedicals)
according to manufacturer’s instructions.
Isolation of monocytes from buffy coats
Human monocytes were isolated from buffy coats of HIV-,
hepatitis B virus-, hepatitis C virus-, human T cell leukemia virus-,
and syphilis-seronegative donors (obtained from the Australian
Red Cross Blood Services, Melbourne) by density-gradient
centrifugation at 9206g for 20 min at room temperature, with
no brake (Ficoll-Paque Plus; Amersham Biosciences), followed by
counter-current elutriation (J-6M/E centrifuge equipped with a
Monocyte Subset CD163 Expression in HIV-1
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monocytes was .90%.
Isolation of monocyte subsets
To obtain purified CD14++CD162, CD14++CD16+ and
CD14+CD16++ monocytes for CD163 mRNA quantification,
PBMC were isolated from 40 ml of freshly collected whole blood by
Ficoll-Paque Plus (Amersham Biosciences) density-gradient centri-
fugation. Amounts not exceeding 1610
8 PBMC were stained with
20 ml anti-CD14 FITC, anti-HLA-DR PE and anti-CD16 PC5 for
30 min on ice before being resuspended at 1610
7/ml in wash
buffer. HLA-DR positive cells were gated onto a CD14 vs. CD16
dot plot and cells defined as CD14++CD162, CD14++CD16+ and
CD14+CD16++ then sorted using a FACSAria (BD Biosciences)
with purities of greater than 95% being achieved for all three
subsets. To obtain monocyte subsets for culture in vitro,5 610
7
elutriated monocytes were stained with 20 ml CD14-FITC and
20 ml CD16-PC5 for 30 min prior to being resuspended in 5 ml
sterile wash buffer then sorted as described above.
Quantification of mRNA in monocyte subsets
To purify mRNA, purified monocyte subsets were lysed using
Buffer A (100 mM Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM
EDTA, pH 8.0, 5 mM DTT and 1% LiDS) and mRNA captured
using GenoPrep Oligo(dT) mRNA Beads as per manufacturer’s
instructions. Messenger RNA was eluted by resuspending washed
beads in 10.4 ml DEPC-treated water and incubating at 65uC for
5 min. Complementary DNA was synthesised by incubating
11.4 ml of mRNA and Anchored-oligo(dT)18 Primer (2.5 mM,
Roche) premix at 65uC for 5 min, followed by addition of 8.6 mlo f
master mix (16 Reaction Buffer, 20 U RNase Inhibitor, 1 mM
dNTPs, 5 mM DTT and 10 U Transcriptor RT) and incubation
at 55uC for 30 min then 85uC for 5 min.
For real-time PCR, 2 ml of 5-fold diluted cDNA was added to
23 ml master mix (12.5 ml SuperArray RT2 Real Time SYBR
Green/Fluorescein PCR master mix (Applied Biosystems), 0.6 mM
primer pair) and real time quantitative PCR (Q-PCR) analysis
performed using an iCycler real-time PCR machine (BioRad). The
CD163 primers were 59-CCAGTCCCAAACACTGTCCT-3
(forward), 59-ATGCCAGTGAGCTTCCCGTTCAGC-39 (re-
verse) and amplified a 67 nucleotide sequence (GenBank accession
number z22968). Relative CD163 mRNA content was determined
by the comparative threshold method using GAPDH PCR as a
comparator: melt curve analysis and agarose gel electrophoresis of
PCR products were conducted to verify that the PCR reaction
amplified a single product in each case.
Figure 1. CD163 is differentially expressed on monocyte subsets at the protein and gene level. (A) Monocytes from whole blood were
identified by forward and side scatter properties and expression of CD14 vs. CD16 with subsets defined as CD14++CD162 (P2, lower right),
CD14++CD16+ (P3, upper right) and CD14+CD16++ (P4, upper left). (B) Expression of CD163 protein (dark grey) in each monocyte subset is shown
compared to matched isotype control (light grey) in the histograms. Data illustrate results from a representative experiment. (C) CD163 mRNA was
determined by Q-PCR in isolated monocyte subsets from 8 HIV-1 negative donors. Bars indicate median values. P values were calculated using the
non-parametric, Mann-Whitney U test adjusted for multiple comparisons.
doi:10.1371/journal.pone.0019968.g001
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monocyte subsets
Monocytes/monocyte-derived macrophages (MDM) were cul-
tured at a concentration of 2610
6 cells/ml in IMDM supple-
mented with 2 mM L-glutamine (both Invitrogen Life Technol-
ogies) and 24 mg/ml gentamicin (supplemented IMDM) with
either 10% heat inactivated pooled human serum (Australian Red
Cross Blood Services, Sydney) in Teflon pots, or 10% fetal calf
serum (ICP Bio) plus M-CSF (50 U/ml, R & D systems) or GM-
CSF (40 ng/ml, kind gift of A. Lopez, Hanson Institute, Adelaide,
Australia) in sterile 5 mm polypropylene tubes (BD Bioscience).
Media was replenished with a half-media change on day 5.
In vitro monocyte and macrophage phenotyping
Monocytes or macrophages (1610
5) were resuspended in 100 ml
of either wash buffer or permeabilisation buffer (0.1% saponin
freshly diluted in wash buffer) for surface or total cellular staining
respectively. Cells were stained with 5 ml anti-CD163-PE or IgG-
PE, or anti-CD206 (mannose receptor)–PE to confirm maturation
[48], for 30 min on ice. Cells were washed once with wash buffer
for surface staining or once with perm buffer and once with wash
buffer for total cellular staining. Cells were then fixed with 3%
formaldehyde and analysed by flow cytometry within 24 hours.
Analysis was carried out using a 7 color FACSAria (BD Bioscience)
with FACSDiva software, or a 3 color FacsCalibur using
CellQuest software (BD Bioscience).
Statistics
Mann-Whitney U test and Wilcoxon matched pairs test was
used to test significant difference for unpaired and paired data
respectively. Non-parametric Spearman correlation coefficient was
used to test correlations. Statistics were generated using GraphPad
Prism 5 and a P value lower than 0.05 was considered significant.
Results
CD163 is differentially expressed on monocyte subsets
and can be induced by M-CSF stimulation.
Expression of CD163 protein on monocyte subsets in whole
blood was investigated within 4 h of venepuncture by flow
cytometry. Blood was collected into K3EDTA-containing vacu-
tainers since the use of both heparin and acid citrate dextran
anticoagulant tubes have been reported to alter CD163 and CD16
protein expression [41,45,49](P. Ellery and SMC unpublished
data). Monocyte subsets were defined as CD14++CD162 (P2),
CD14++CD16+ (P3) and CD14+CD16++ (P4) as shown in
figure 1A. CD163 expression was greatest on CD14++CD162
monocytes (median MFI [IQR]=201.0 [176.0–374.0]), expressed
at an intermediate level on CD14++CD16+ monocytes (192.0
[113.0–263.0]) and low/undetectable on CD14+CD16++ mono-
cytes (5.0 [0–39.0]) A representative histogram of CD163 staining
for each subset from a single donor is presented (Figure 1B).
To determine whether the difference in CD163 protein
expression between monocyte subsets was at the level of gene
expression, CD163 mRNA was quantified in the three monocyte
subsets purified from eight healthy HIV-uninfected subjects
(Figure 1C). CD163 mRNA expression showed a similar pattern
of expression to CD163 surface expression, that is, highest in
CD14++CD162 monocytes and undetectable in CD14+CD16++
monocytes. These data show that the three monocyte subsets
express different amounts of CD163 on their surface and that this
is consistent with the relative level of CD163 mRNA in each
subset.
To systematically investigate the effect of Ficoll density gradient
isolation on monocyte subsets we performed a pair-wise
comparison of the percentage of monocytes that expressed
CD163 in whole blood and after PBMC preparation. CD163
expression was reduced on CD14++CD162 monocytes present in
PBMC preparations compared to whole blood from the same
donor by a median of 24.8% (n=21, P=0.0003) (Figure 2A). The
proportion of CD163 positive cells in the CD14++CD16+
monocyte subset from whole blood and PBMCs were similar in
eight donors tested (P=0.38). These data suggest that CD163
expression on CD14++CD162 monocytes is altered by sample
manipulation and that surface expression on this subset may be
more labile than on other monocyte subsets.
To determine if the degree of cleavage of CD163 from the cell
surface differed in different monocyte subsets, we stimulated
monocytes from 4 HIV-1 negative donors with LPS to induce
shedding (Figure 2B)[31,32,33,34]. The mean fluorescence
Figure 2. Surface CD163 expression is reduced on
CD14++CD162 monocytes after density gradient separation
and LPS stimulation. (A) Comparison of CD163 protein expression on
the classical CD14++CD162 subset was carried out on 13 samples from
HIV-1 negative donors and on all monocyte subsets from a further eight
donors before and after Ficoll density gradient purification of PBMC
from whole blood. Bars represent median values. Differences were
analysed using the Wilcoxon matched pairs test. WB: whole blood,
PBMC: peripheral blood mononuclear cells. (B) Whole blood from HIV-
uninfected donors was incubated with 1 mg/ml LPS for 2 h and CD163
surface expression measured by flow cytometry. CD163 expression on
each subset (mean fluorescence intensity) is plotted as the ratio of
expression in treated compared to untreated monocytes. Data
represent mean 6 SEM for 4 independent donors. ‘ data from 1 donor
was excluded from the CD14++CD16+ data set due to insufficient cell
number.
doi:10.1371/journal.pone.0019968.g002
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decreased by an average of 19.7% in LPS treated monocytes
compared to controls (mean MFI 503 untreated vs. 404 in LPS
treated CD14++CD162 monocytes). In contrast, LPS treatment
had no effect on detection of CD163 in CD14++CD16+ (mean
MFI 557 untreated vs. 616 LPS treated) or CD14+CD16++ (87
untreated vs 126 LPS treated) monocyte subsets indicating that the
majority of CD163 is shed from the major CD14++CD162
monocyte population after LPS stimulation.
To determine how CD163 protein expression changes with
differentiation of monocytes to macrophages, monocytes isolated
by counter-current elutriation (n=5 donors) were cultured under
non-adherent conditions in IMDM supplemented with human
serum but no additional growth factors. Total and surface CD163
expression and surface mannose receptor expression was measured
at various times during maturation of monocytes to monocyte-
derived macrophages (MDM) (Figure 3). As expected, monocytes
did not express mannose receptor [48,50], but following
differentiation into macrophages its expression was detectable on
the majority of cells. The frequency of CD163 expressing MDM
rapidly increased after five days in culture, reaching a maximum
after 10 days. A comparison of surface CD163 staining versus
staining following permeabilisation showed the presence of high
levels of intracellular CD163. After 10 days of culture, an average
of 70.8612.8% (mean 6 standard deviation) of MDM contained
intracellular/surface CD163. However, a substantial proportion
(35.7617.8%) of MDM expressing intracellular CD163 did not
express detectable CD163 on the cell surface. The total MFI at the
same time point was 2.5 times greater than surface alone
(16396504 vs. 6356171 fluorescence units). The fact that
CD163 is predominantly expressed intracellularly in macrophages
and not on the surface membrane as occurs in monocytes suggests
that the function of CD163 in monocytes may differ to that of
macrophages.
To address whether all three monocyte subsets are able to
differentiate into CD163-expressing MDM, irrespective of initial
levels of CD163 gene expression, subsets were isolated from
elutriated monocytes by FACS and cultured separately in the
presence of M-CSF (n=4) or GM-CSF (n=2) for eight days prior
to determination of surface and total CD163 protein expression.
Expression of CD163 protein increased in each monocyte subset
to similar levels when cells were cultured with M-CSF (Table 1).
Culture of monocytes from all three subsets in the presence of
GM-CSF resulted in negligible expression of surface CD163.
Intracellular CD163 was still detectable in an average of 32.8% of
the CD14++CD162 population but only in #5% of
CD14++CD16+ and CD14+CD16++ monocytes (Table 1). These
results show that CD163 expression is highly inducible, is readily
modified by macrophage growth factors and has the capacity to be
expressed by all three monocyte subsets.
CD163 expression is increased on CD14++CD16+
monocytes from HIV-1 infected donors.
We next compared CD163 protein expression on monocytes
from HIV-infected individuals (n=38), of whom 30 were currently
receiving antiretroviral therapy, with 26 age-matched, healthy
HIV-uninfected donors. The median CD4 T cell count and viral
load for this HIV-1 cohort was 535 cells/ml and most had an
undetectable viral load (,50 copies/ml) with only 9 participants
having detectable viremia (Table S1). HIV-1 infected donors
showed the same pattern of expression of CD163 across their
monocyte subsets as uninfected donors, with the CD14++CD162
subset having the highest frequency and CD14+CD16++
monocytes the lowest frequency of CD163 expressing monocytes
(Figure 4Ai). When we compared expression of CD163 on each
subset in HIV-infected and uninfected donors we found
significantly higher expression of CD163 on CD14++CD16+
monocytes in HIV-1 infected donors compared to HIV-1
uninfected donors (38.5% vs 29.6% respectively, P=0.021). In
CD14++CD162 monocytes expression of CD163 was higher in
HIV-1 infected donors compared to HIV-1 uninfected donors,
Figure 3. Intracellular and surface CD163 expression increases
during maturation of monocytes to macrophages. Monocytes
purified by countercurrent elutriation from healthy HIV-1 uninfected
donors were cultured in vitro for the times indicated, then stained for
CD163 with (solid line) and without (dashed line) permeabilisation to
measure total (surface and intracellular) and surface only CD163,
respectively. At the same time, cells were stained for expression of
mannose receptor to confirm maturation of monocytes into macro-
phages. Percent of monocytes/macrophages positive for CD163 is
presented in upper graph and mean fluorescence intensity of
expression in middle graph. Percent of monocytes/macrophage
positive for mannose receptor is presented in lower graph. Data
represent mean 6 SEM using 5 independent donors.
doi:10.1371/journal.pone.0019968.g003
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65.5% respectively, P=0.069).
As CD163 is shed via proteolytic cleavage [51], patients were
stratified based on their receiving antiretroviral therapy regimens
containing or not-containing a protease inhibitor (PI) and CD163
expression was compared on monocyte subsets. Patients treated
with PIs (n=8) expressed higher levels of CD163 on
CD14++CD162 monocytes compared to those on a non-PI
containing regimen, although this did not reach statistical
significance (P=0.056), possibly due to low sample size in the PI
group. CD163 expression was not increased on CD14++CD16+
monocytes (P=0.34) from patients on a PI compared to patients
(n=22) receiving non PI-containing regimens. This suggests that
PIs may affect expression of CD163 on CD14++CD162
monocytes and confound measurement of CD163 on this subset
in HIV patients. Exclusion of patients being treated with PIs from
the analysis resulted in there being no difference in CD163
expression on CD14++CD162 monocytes of HIV+ patients
compared to HIV-1 negative donors (P=0.25), but a trend
towards a difference in CD14++CD16+ monocytes (P=0.06).
There was no difference in the proportion of monocytes within
each subset between HIV-1 infected and uninfected donors
(Figure 4Aii) indicating that differences in CD163 expression
between these two groups are not due to changes in CD16 protein
expression in HIV-1 infection.
We next quantified soluble CD163 by sandwich ELISA using
plasma from a randomly chosen subset of the HIV-1 uninfected
donors (n=11) and a cohort of HIV-1 infected donors (n=38)
separate from that used above (Figure 4B). In this selected group of
HIV-1 infected donors median T cell count was 465 cells/ml and
median viral load was 835 copies/ml with 22 out of 38 donors
having a detectable viral load; 15 were not receiving antiretroviral
therapy. There was no significant difference in plasma sCD163
concentrations between these two groups (median [IQR] HIV-
infected=3.0 [4.322.0], HIV-uninfected=3.6 [4.321.6] mg/ml
P=0.87), nor between patients on therapy being treated with or
without a protease inhibitor (P=0.54).
It has been reported previously in HIV-infected individuals with
a CD4 count of less than 450/ml that the frequency of CD163
positive cells inversely correlated with CD4 counts [52]. We
therefore examined the relationship between CD163 protein
expression on both monocyte subsets and CD4 counts of the
cohort, analysing expression on monocytes from patients with
CD4 counts greater than or less than 500 cells/ml (Figure 5). A
plot of CD163 surface expression on both the CD14++CD162
and CD14++CD16+ monocyte subsets with the patients’ CD4 T
cell counts at time of recruitment showed a biphasic relationship.
HIV-1 infected patients with a CD4 count #500 cells/ml showed
an inverse correlation between CD4 count and the percentage of
CD14++CD162 monocytes expressing CD163 (rs=20.55,
P=0.027) and CD14++CD16+ monocytes expressing CD163 (rs
20.60, P=0.014). Conversely, HIV-1 positive patients with a
CD4 T cell count .500/ml showed a positive correlation between
CD163 expression and CD4 counts (rs=0.43, P=0.053, for
CD14++CD162 monocytes and rs=0.67, P=0.0008 for
CD14++CD16+ monocytes). For both CD4 T cell counts . and
,500, the CD14++CD16+ subset demonstrated the strongest
correlation based on both P and rs value. Data were also examined
following exclusion of results from patients being treated with PIs.
For patients being treated with a non-PI containing regimen with
CD4 counts less than 500/ml the correlation between CD4 count
and surface CD163 expression was strengthened for both
CD14++CD162 and CD14++CD162 monocytes (rs=20.67,
P=0.009 and rs=20.68, P=0.008 respectively). There was no
correlation between patient viral load and surface CD163 on
either monocyte subset (data not shown).
Examination of sCD163 levels and CD4 T cell count showed a
weak correlation (rs=0.34), such that patients with low CD4 T cell
counts had low sCD163 levels (Table S2). Further analysis of both
sCD163 and surface CD163 expression compared to CD4 cell count
in various clinical groups is presented in supplementary data table S2.
Discussion
In this study we have used whole blood flow cytometric
phenotyping assays and quantitative real time PCR to show that
CD163 is expressed in high levels on the classical CD14++CD162
monocytes, intermediate levels on CD14++CD16+ monocytes and
not at all on non-classical CD14+CD16++ monocytes. We show
that CD163 surface expression is decreased selectively on
CD14++CD162 monocytes during monocyte purification which,
together with variable antibody affinities [46], explanat the
discrepancies in the literature regarding monocyte expression of
CD163 [25,52]. We further show that all monocyte subsets induce
comparable CD163 expression following differentiation to type 2
(anti-inflammatory) macrophages in the presence of M-CSF which
suggests that CD163 positive macrophages are not derived
exclusively from CD163 expressing monocytes. Finally, we show
that CD163 is elevated on monocytes from HIV-1 infected
individuals. These data support the hypothesis that CD163 could
serve as a biomarker for immune activation and/or resolution of
inflammation in HIV-infected individuals in the HAART era
[5,6,7,13,32,39,53].
There are several conflicting reports regarding CD163 protein
expression on monocyte subsets. The reported frequency of
CD163 positive monocytes from healthy individuals has ranged
from undetectable to as high as 100% [54,55]. CD163 protein
expression on monocyte subsets has also previously been reported
to be highest on CD16+ monocytes [25]. We demonstrate that
CD163 is detectable by flow cytometry on the majority of
CD14++CD162 monocytes and in approximately half of
CD14++CD16+ monocytes. These findings are similar, albeit at
a lower level, to those reported by Monisuszko et al. [20]. In
contrast to several reports [20,25], however, we found surface
CD163 is undetectable in CD14+CD16++ monocytes ex vivo.
These findings are reflected by CD163 gene expression measured
by real time RT-PCR. The differential expression of CD163
between subsets may reflect distinct monocyte subset functions,
with the absence of CD163 on CD14+CD16++ monocytes
consistent with their pro-inflammatory role [56,57].
Table 1. Mean percent of cells expressing CD163 after culture
of the monocytes in M-CSF or GM-CSF.
n CD14++CD162 CD14++ CD16+ CD14+ CD16++
M-CSF
Surface 4 24.765.5 25.266.2 19.065.7
Total 4 51.064.6 68.864.0 52.864.8
GM-CSF
Surface 2 0.060.6 20.360.4 20.560.1
Total 2 32.8614.7 5.266.3 1.961.5
Surface and total CD163 expression were measured on macrophages derived
from each of the indicated monocyte subsets cultured for 8 days in the
presence of M-CSF or GM-CSF.
doi:10.1371/journal.pone.0019968.t001
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CD163 expression on monocyte subsets are likely to be due to a
range of technical issues. These include anticoagulant type
[52,58,59], antibody used (relating to access to epitope as well as
extracellular calcium dependence [46]), analysis of PBMC
prepared using Ficoll density gradient isolation [52,58,59] and
monocyte culture prior to analysis [25,60]. These incongruities
highlight the need for techniques of measuring CD163 expression
that involve the least amount of sample manipulation, such as
using whole blood techniques.
Examination of the effect of sample manipulation on expression
of CD163 on the surface of monocytes confirmed observations by
others [45]. However, we further show that whilst CD163
expression was significantly decreased on CD14++CD162
monocytes following sample manipulation, expression on
CD14++CD16+ monocytes was not changed following Ficoll
density gradient centrifugation. This suggests that CD163 is more
labile on the former subset. To investigate this observation we
induced CD163 shedding by LPS and found similarly reduced
CD163 surface expression on CD14++CD162 monocytes but
comparable levels on CD14++CD16+ monocytes compared to
controls.
CD163 surface expression has been shown to be altered by
cleavage of CD163 mediated by a metalloproteinase, specifically
ADAM17 (a disintegrin and metalloproteinase domain 17) [51],
rather than loss of epitopes due to conformational changes or
protein internalisation [31,32,33,34]. Monocyte subsets differen-
tially express metalloproteinases [61,62]. This most likely accounts
for the different degree of CD163 shedding between the subsets
demonstrated here, however, ADAM17 expression has not yet
been characterised on monocyte subsets. Our observations
showing an LPS-induced decrease in CD163 expression on the
classic CD14++CD162 monocytes but not CD14++CD16+
monocytes suggest that the majority of CD163 found as sCD163
in plasma originates from CD14++CD162 monocytes.
CD163 expression on monocytes and macrophages is readily
modified by immune factors such as cytokines, inflammatory
mediators and bacterial components. We showed that when
monocytes are matured into macrophages CD163 expression is
upregulated and that a significant proportion of CD163 is found
Figure 4. Membrane bound and soluble CD163 in monocyte subsets from HIV-1 infected donors. (A.i) CD163 expression on each
monocyte subset was determined using a whole blood flow cytometric assay for HIV-1 uninfected donors (closed circles, n=27) and infected donors
(open squares, n=38). Bars represent median values. (A.ii) The proportion of total monocytes in each of the three monocyte subsets was determined
for each donor analysed in (A.i). The event count for that subset was divided by the sum of events in each subset. Bars represent median values.
(B) Soluble CD163 in serum from 12 HIV uninfected donors, 38 HIV-1infected donors receiving antiretroviral therapy was determined by sandwich
ELISA. Bars represent median values. P values were calculated using the non-parametric Mann Whitney U test.
doi:10.1371/journal.pone.0019968.g004
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maintained to enable rapid secretion upon stimulation, or may
indicate constitutive endocytosis [63]. To investigate the potential
for each subset to express CD163, isolated monocyte subsets were
differentiated [64] in the presence of GM-CSF and M-CSF. Using
this experimental protocol circumvents the problems resulting
from the low viability of CD16+ monocytes cultured in the
absence of added cytokines, and provides additional information
regarding pro-inflammatory type 1 and anti-inflammatory type 2
macrophages [64]. Expression of CD163 on monocyte-derived
macrophages from each subset was low after culturing in the
presence of GM-CSF, supporting previous observations [64,65].
In contrast, MDM derived from monocyte subsets cultured in the
presence of M-CSF upregulated CD163 in each subset to
comparable levels. These data indicate that despite undetectable
mRNA levels in circulating CD14+CD16++ monocytes CD163
expression can be induced by M-CSF to levels comparable to the
CD14++CD162 population.
It is uncertain whether different monocyte subsets have different
differentiation fates in vivo. Our findings have implications
regarding the origin of perivascular macrophages in the brain
which express both CD16 and CD163. Several reports have
suggested that CD14+CD16+CD163+ monocytes circulating in
the peripheral blood are potentially the precursors of perivascular
macrophages due to the similarity in phenotype [41,52]. Given
that CD16 is induced during monocyte maturation [66] and that
we have shown that CD163 can be expressed in any monocyte
subset upon stimulation, these markers are not reliable in
predicting the origin of perivascular macrophages. As monocyte
subsets can be matured into cells with distinct functional
characteristics in vitro [67], further work is required to determine
if, despite similar CD163 expression, type II macrophages derived
from different subsets have differences in immune function such as
bacterial phagocytic or T cell stimulating ability.
Our data show that the frequency of CD14++CD162CD163+
and CD14++CD16+CD163+ monocytes from HIV-infected
individuals was increased relative to age-matched, HIV-uninfected
individuals, with differences in the latter subset reaching statistical
significance. There was no significant change in the proportion of
each monocyte subset to total monocytes from HIV-1 infected
donors, the majority of whom were on HAART with an
undetectable viral load, compared to HIV-uninfected controls
(similar to our earlier observations [68]) and so this finding was not
due to upregulation of CD16 during HIV-1 infection. Comparison
of CD163 expression on monocytes from patients receiving or
not receiving a PI-containing regimen suggests that protease
inhibitors may selectively decrease cleavage of CD163 from
CD14++CD162 monocytes, accounting for the trend to increased
CD163 expression seen in HIV-infected versus HIV-1 uninfected
donors. In their study, Fischer-Smith et al. did not demonstrate
increased CD163 expression on CD14++CD162 monocytes from
HIV-1 infected donors [52]. This may be due to a range of factors,
Figure 5. Membrane CD163 expression is related to CD4 T cell count. Frequency of CD163 positive cells in CD14++CD162 monocytes (top
row) and CD14++CD16+ monocytes (bottom row) was correlated with CD4 T cell count for donors below 500 cells/ml (left column) and above
500 cells/ml (right column). Donors not currently receiving antiretroviral therapy are represented by open circles and donors receiving protease
inhibitors are represented by dotted squares. rs and P values after analysis excluding patients receiving PI are presented in parentheses after pooled
data. rs value was determined by Spearman correlation coefficient.
doi:10.1371/journal.pone.0019968.g005
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as examination of phenotype on PBMC post Ficoll isolation which
we have shown to selectively result in loss of CD163 from
CD14++CD162 monocytes. We did not find any association
between receiving a PI-containing regimen and levels of sCD163
in plasma, but this is presumably due to the low numbers of our
patients receiving PIs. Direct comparison of CD163 expression on
CD14++CD162 monocytes and soluble CD163 levels in single
donors from a larger cohort may uncover a connection between
these parameters.
We observed a weak overall correlation between sCD163 levels
and CD4 T cell counts with no correlation between sCD163 and
HIV RNA. Previously, Fischer-Smith et al. reported an inverse
correlation between frequency of CD163+CD14++CD16+ mono-
cytes and CD4 T cell count in HIV-1 positive donors with counts
below 450 cells/ml [52]. We stratified our surface expression data
based on the commonly used and thus more clinically relevant
CD4 cutoff of 500 cells/ml and correlated CD163 expression with
CD4 counts. Whilst we found a similar negative correlation
between CD163 positive monocyte frequency and CD4 counts in
patients with low CD4 counts (for both CD14++CD16+
monocytes as well as CD14++CD162 monocytes), our data also
show a positive correlation in both monocyte subsets in donors
with T cell counts above 500 cells/ml. These observations were
similar when we stratified our patients using the same CD4 cutoff
as Fischer–Smith and colleagues. These findings are intriguing and
suggest alteration in CD163 expression on CD14++CD16+
monocytes in HIV-infected individuals may reflect either HIV-
or immune–related influences on CD163 gene and protein
expression and shedding. This might include an altered cytokine
milieu in individuals at different stages of disease e.g. raised plasma
IL-10 and cortisol [23,25,54,69,70] (reviewed [71]), defects in
cleavage of CD163 as a consequence of HIV-1 therapy,
contribution from comorbid illness such as cardiovascular disease,
or possibly alterations in gut lymphoid mass with resulting
bacterial translocation [72,73]. To fully elucidate the factors that
modulate CD163 expression in HIV-1 patients, larger cohorts
stratified on therapy type and comorbid disease are required.
Several studies have investigated changes in both membrane
bound and soluble CD163 in response to acute illness.
Examination of sCD163 levels in hospitalised patients demon-
strated that sCD163 is an acute phase marker which increases in
response to bacterial infection [5,8,32,35,36,37,74]. We did not,
however, find such a correlation in our cohort of HIV-1 infected
donors. Administration of endotoxin to healthy human subjects
results in a rapid increase in sCD163 levels with concomitant loss
of membrane expression on monocytes [33]. Given that LPS levels
are elevated in plasma of HIV-infected patients, even in those
whose viremia is suppressed by ART [72,73], we predicted that
CD163 expression on CD14++CD162 monocytes would be
decreased and sCD163 levels increased. However, we show that
membrane bound CD163 in fact increases and there is no
detectable change in sCD163 levels in HIV-1 infection. Recent
investigation into the effect of chronically raised LPS serum levels
on monocyte activation in HIV-1 infected people demonstrated
that monocytes become resistant to the stimulating effect of LPS
[75]. Monocyte tolerance to endotoxin may explain why we did
not find increased sCD163 plasma levels and the typical changes
in CD163 expression seen after acute exposure to endotoxin in vivo
[33]. As CD163 is involved in immune resolution, abrogated
CD163 responses to inflammatory stimuli may contribute to the
observed chronic immune activation/inflammation that is char-
acteristic of HIV infection. Further investigation into the effect of
chronic bacterial translocation on CD163 expression and shedding
in HIV-1 infection, and correlation with other markers of
inflammation, may uncover a better understanding of chronic
immune activation in HIV-1 infection.
The development of biomarkers that reflect chronic inflamma-
tion and/or immune activation is critical to ensure better long
term outcomes for people with HIV-1. CD163 shows potential
promise as a biomarker of monocyte/macrophage activation, but
our data suggest that a complex relationship exists between
CD163 monocyte expression and shedding on the one hand and
HIV disease progression on the other. Further studies are
warranted to define these relationships before CD163 could be
used as a prognostic indicator of HIV-1 related co-morbidities.
In the early days of antiretroviral therapy, goals for treatment
focused on maintaining life. Due to the success of combination
antiretroviral therapy focus has shifted to maintaining the health of
HIV-infected individuals. Current antiretroviral therapy, despite
effective viral suppression, does not eliminate immune activation
and chronic inflammation persists, leading to an increased
incidence of age-associated inflammatory diseases and a shortened
lifespan. As CD163 is involved in immune resolution and
protection against the development of atherosclerotic plaques,
understanding the changes in regulation of CD163 in HIV-1 is
important in addressing comorbid diseases caused by chronic
immune activation.
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